Objective: To provide an overview of the formulations designed and developed to date based on synthetic siRNA for systemic administration to silence cancer genes.
First-pass extracted concept
synthetic siRNA formulations for systemic cancer gene silencing
Candidate: concept label1 source documents5 linked claims
Live refresh every 5sNext refresh in 5s
Evidence Snippets
Supporting Sources
Linked Claims
siRNA therapies provide a flexible platform for targeting and inhibiting critical oncogenes, supporting genomics-guided patient-specific therapies.
Personalized cancer therapy tailored to the patient's genetic profile is presented as the preferred direction for oncological treatment progress.
The review covers siRNA design using bioinformatics tools, targeted cellular signals and mechanisms, chemical modification strategies, and carrier formulations including conjugates and organic, inorganic, and hybrid nanoparticles.
Numerous studies have demonstrated therapeutic potential of siRNA formulations for tumor remission.
siRNA formulations have not yet been approved for cancer therapy.